Healthcare / Medical Instruments & SuppliesKOSDAQ
$9710.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-264.7M · quality 47.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$286.2B
P/E
334.8x
↑EV/EBITDA
126.1x
↑ROE
1.9%
↑Gross Margin
63.6%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-16.8%
FCF CAGR
—
FCF margin
-68.4%
FCF / Net income
-5.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.03B · net income $851.6M · FCF $-4.81B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.03B | $7.03B | $5.27B | $4.09B | $12.21B |
| Net Income | $851.6M | $851.6M | $10.8M | $-991.8M | $5.61B |
| EBITDA | $2.16B | $2.16B | $1.48B | $444.7M | $8.92B |
| EPS | 29.00 | 29.00 | 0.37 | -6.60 | 37.80 |
| Gross Margin | 63.6% | 63.6% | 46.2% | 16.7% | 76.2% |
| Operating Margin | 9.3% | 9.3% | -32.8% | -50.2% | 54.7% |
| Net Margin | 12.1% | 12.1% | 0.2% | -24.3% | 46.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 27.99 | 27.99 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.81B | $-4.81B | $338.3M | $-264.7M | $1.02B |
| Returns | |||||
| ROE | 1.9% | 1.9% | 0.0% | -2.3% | 12.7% |
| Valuation | |||||
| P/E | 334.83 | 334.83 | 45815.57 | — | 658.73 |
| EV/EBITDA | 126.05 | 126.05 | 329.93 | 20961.87 | 84.92 |
| P/B | 6.47 | 6.47 | 11.42 | 215.10 | 17.40 |
| Growth & Yield | |||||
| Revenue Growth | 33.3% | 33.3% | 28.9% | -66.5% | — |
| EPS Growth | 7837.0% | 7837.0% | 105.5% | -117.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
209.7%
EPS terminal req.
$861.60
Spread vs growth
7627.3%
5Y implied EPS CAGR
104.7%
EPS terminal req.
$1042.54
Spread vs growth
7732.3%
10Y implied EPS CAGR
50.1%
EPS terminal req.
$1679.02
Spread vs growth
7786.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-42.2%
Start / end P/E
45952.4x → 334.8x
EPS bridge
0.37 → 29.00
Residual
-7779.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.